Cancer clinical trials in the region Auvergne-Rhône-Alpes

502 currently recruiting clinical trials
Region Auvergne-Rhône-Alpes
Phase 2 Lymphoma #NCT06558604 #2023-506706-40-00
Required histologic types
B cell lymphoma
Required histologic sub types
Mantel cell lymphoma
Required disease stage
Early (stage I and II) Disseminated (stage III and IV)
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min 50-60 ml/min 30-50 ml/min
Required number of previous lines of therapy
1
Required previous treatments
Chemotherapy Targeted therapy
Excluded previous treatments
Bispecific T-cell engager antibodies
13 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 2 Head and neck cancer #NCT06172478 #2023-507641-29-00
Carcinomes épidermoïdes de la tête et du cou
Required histologic types
Oral cavity Oropharynx Hypopharynx Larynx
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Daiichi Sankyo
Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT06682988 #2024-517184-23-00
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Required folate alpha receptor score
Greater than or equal to 75%
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required platino resistance
Recurrence within 6 months after platinum-based tr...
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
8 recruiting sites
Abbvie
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT04116541 #2023-510567-35-00
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
BRAF
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
Centre Léon Bérard
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT04116541 #2023-510567-35-00
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
ALK
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
Centre Léon Bérard
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT04116541 #2023-510567-35-00
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
Centre Léon Bérard
Phase 2 Lung cancer #NCT07288177 #2025-522107-18-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Genmab
Phase 2 Chronic myeloid leukemia (CML) #NCT02889003
Required number of previous lines of therapy
1
Required previous treatments
ATP pocket inhibitor Allosteric inhibitor
Excluded genetic anomalies
BCR-ABL
Excluded previous treatments
Systemic Treatment-Naive Allogeneic stem cell transplant
3 recruiting sites
Hôpital de Versailles
Phase 2 Acute leukemia #NCT07007052 #2024-511003-42-00
Required histologic types
Blastic plasmacytoid dendritic cell neoplasm (BPDC...
Required renal function statuses
> 60 ml/min
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
8 recruiting sites
French Innovative Leukemia Organisation (FILO)
Phase 2 Lymphoma #NCT05139017 #2022-502646-27-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required central nervous system lesions
None Treated / Controled
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Car-T Autologous stem cell transplant
Excluded previous treatments
Systemic Treatment-Naive
2 recruiting sites
Merck Sharp & Dohme LLC